Dignity Weight Center only prescribes FDA-approved medications
Improved Metabolic Health: Beyond weight loss, semaglutide has been associated with improvements in metabolic parameters such as blood sugar levels and insulin sensitivity
The STEP UP trial, published in The Lancet Diabetes & Endocrinology in September 2025, showed 18.7% average weight loss at 72 weeks compared to 15.6% at the standard 2.4 mg dose
The idea is that lasting results come from behavior change supported by medication, not medication alone
Beyond lowering HbA1c levels, these medications often reduce cardiovascular risks and may even slow the progression of kidney disease in people with diabetes
Datos toxicolgicos preclnicos: Los estudios de toxicidad aguda y subaguda en la rata no han evidenciado mortalidad ni toxicidad orgnica significativa, incluso a dosis ampliamente superiores a las dosis teraputicas (hasta 100 veces la dosis eficaz)